Opthea Limited Market Cap ($2.94 Million)
Market Cap & Net Worth: Opthea Limited (OPTEY)
Opthea Limited market cap. Opthea Limited (NASDAQ:OPTEY) has a market capitalization of $2.94 Million ($2.94 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29498 globally and #6027 in its home market, demonstrating a -22.17% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Opthea Limited's stock price $0.02 by its total outstanding shares 170997272 (171.00 Million). Also see OPTEY cash flow conversion for how efficiently the company converts equity into cash flow.
Opthea Limited Market Cap History (2025–2026)
Opthea Limited market cap history from 2025 to 2026. Data shows growth from $4.02 Million to $2.94 Million (0.00% CAGR). Check OPTEY stock price for real-time trading data and today's change.
Opthea Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Opthea Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Opthea Limited growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
160.74x
Opthea Limited's market cap is 160.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $4.02 Million | $25.00K | -$162.79 Million | 160.74x | N/A |
Competitor Companies of OPTEY by Market Capitalization
Companies near Opthea Limited in the global market cap rankings as of November 4, 2026. Also see how large is Opthea Limited's balance sheet for a full breakdown of the balance sheet.
Key companies related to Opthea Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Opthea Limited (2025–2026)
Market capitalization of Opthea Limited from 2025 to today. Between 2025 and today, Opthea Limited's market cap moved from $4.02 Million to $ 2.94 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.94 Million | -26.81% |
| 2025 | $4.02 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Opthea Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.94 Million USD |
| MoneyControl | $2.94 Million USD |
| MarketWatch | $2.94 Million USD |
| marketcap.company | $2.94 Million USD |
| Reuters | $2.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Opthea Limited
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more